JAK2 V617F Mutation in Adult Taiwanese Patients with Essential Thrombocythemia: More Prevalent in Old Patients and Correlated with Higher Hemoglobin Level and Higher Leukocyte Count

Wadleigh, 2010, Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria, Int J Hematol, 91, 174, 10.1007/s12185-010-0529-5 Swerdlow, 2008 Fialkow, 1981, Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell, Blood, 58, 916, 10.1182/blood.V58.5.916.916 Campbell, 2006, The myeloproliferative disorders, N Engl J Med, 355, 2452, 10.1056/NEJMra063728 Rozman, 1991, Life expectancy of patients with chronic nonleukemic myeloproliferative disorders, Cancer, 67, 2658, 10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C Tefferi, 2001, A long-term retrospective study of young women with essential thrombocythemia, Mayo Clin Proc, 76, 22, 10.4065/76.1.22 Schafer, 2006, Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia, Blood, 107, 4214, 10.1182/blood-2005-08-3526 Elliott, 2005, Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia, Br J Haematol, 128, 275, 10.1111/j.1365-2141.2004.05277.x Tefferi, 2009, TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia, 23, 905, 10.1038/leu.2009.47 Levine, 2005, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, 7, 387, 10.1016/j.ccr.2005.03.023 Baxter, 2005, Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, Lancet, 365, 1054, 10.1016/S0140-6736(05)74230-6 James, 2005, A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, 434, 1144, 10.1038/nature03546 Kralovics, 2005, A gain-of-function mutation of JAK2 in myeloproliferative disorders, N Engl J Med, 352, 1779, 10.1056/NEJMoa051113 Campbell, 2005, Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study, Lancet, 366, 1945, 10.1016/S0140-6736(05)67785-9 Gangat, 2007, Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients, Leukemia, 21, 270, 10.1038/sj.leu.2404500 Wolanskyj, 2005, JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance, Br J Haematol, 131, 208, 10.1111/j.1365-2141.2005.05764.x Kittur, 2007, Clinical correlates of JAK2V617F allele burden in essential thrombocythemia, Cancer, 109, 2279, 10.1002/cncr.22663 Cheung, 2006, The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia, Br J Haematol, 132, 244, 10.1111/j.1365-2141.2005.05858.x Zhang, 2008, JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera, Leuk Lymphoma, 49, 696, 10.1080/10428190701885537 Toyama, 2007, JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets, Br J Haematol, 139, 64, 10.1111/j.1365-2141.2007.06755.x Wong, 2008, JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia, Br J Haematol, 141, 902, 10.1111/j.1365-2141.2008.07127.x Chen, 2007, Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders, Am J Hematol, 82, 458, 10.1002/ajh.20872 Lieu, 2008, Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders, Intern Med J, 38, 422, 10.1111/j.1445-5994.2007.01589.x Wong, 2011, JAK2 Mutations in Asian patients with essential thrombocythaemia, Intern Med J, 41, 191, 10.1111/j.1445-5994.2010.02199.x Hsiao, 2007, The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia, Exp Hematol, 35, 1704, 10.1016/j.exphem.2007.08.011 Vannucchi, 2008, Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal, Leukemia, 22, 1299, 10.1038/leu.2008.113 Cho, 2009, Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia, Int J Hematol, 89, 39, 10.1007/s12185-008-0222-0 Randi, 2011, JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia, Aging Clin Exp Res, 23, 17, 10.1007/BF03324948 Antonioli, 2005, Clinical implications of the JAK2 V617F mutation in essential thrombocythemia, Leukemia, 19, 1847, 10.1038/sj.leu.2403902 Pemmaraju, 2007, The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis, Leukemia, 21, 2210, 10.1038/sj.leu.2404755 Finazzi, 2007, Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status, Haematologica, 92, 135, 10.3324/haematol.10634 Rudzki, 2007, The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more “erythremic” and less “thrombocythemic”: a molecular, histologic, and clinical study, Int J Hematol, 86, 130, 10.1532/IJH97.E0607 Heller, 2006, JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status, Eur J Haematol, 77, 210, 10.1111/j.1600-0609.2006.00688.x Alvarez-Larran, 2007, Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients, Leukemia, 21, 1218, 10.1038/sj.leu.2404693 Vannucchi, 2007, Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia, Blood, 110, 840, 10.1182/blood-2006-12-064287 Antonioli, 2008, Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia, Haematologica, 93, 41, 10.3324/haematol.11653 Kralovics, 2006, Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders, Blood, 108, 1377, 10.1182/blood-2005-11-009605 Lussana, 2009, Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review, Thromb Res, 124, 409, 10.1016/j.thromres.2009.02.004 Barbui, 2011, Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet, J Clin Oncol, 29, 761, 10.1200/JCO.2010.31.8436